Does increasing the biltricide (praziquantel) treatment frequency reduce liver damage in children?

Impact of increased praziquantel frequency on childhood fibrosis in persistent schistosomiasis morbidity hotspots. A phase IV CTIMP trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN16994599

Enrollment

600

Registered

2019-09-05

Start date

2020-02-20

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periportal fibrosis of the liver caused by schistsosomiasis mansoni Digestive System Hepatic fibrosis

Interventions

Current intervention as of 12/04/2023: This trial is designed to align with the national Uganda Neglected Tropical Disease Control Programme, Mass Drug Administration with Praziquantel (MDA), which is

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Have a parent/guardian who has given written/marked informed consent for the child to participate 2. Given written/marked informed assent to participate 3. Aged 6-14 years of age 4. Born or resident within the community in which their school is situated for >=2 years

Exclusion criteria

Exclusion criteria: 1. History of facial oedema after treatment with praziquantel Added 12/06/2020: 2. Known neurocysticercosis or ocular cysticercosis

Design outcomes

Secondary

Measure	Time frame
Schistosoma mansoni infection intensities are measured using Kato-Katz faecal egg counts at 2-year follow-up	—

Primary

Measure	Time frame
Prevalence of periportal fibrosis, defined as Niamey Protocol pattern scores of C, D, E or F, measured at 2-year follow-up	—

Countries

Uganda

Contacts

Public ContactKatrina Gatley

cuh.cctu@nhs.net+44 (0)1223 216740

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026